. Platelet-activating factor and prostaglandin E 2 impair esophageal ACh release in experimental esophagitis.
IT IS KNOWN THAT cytokines are involved in most aspects of inflammation in organs and systems, including intestinal inflammation. IL-1␤, IL-6, and TNF-␣ are the major proinflammatory cytokines involved in the inflammatory cascade. Enhanced production of IL-1 has been demonstrated in animal models of intestinal inflammation (20) , in the colonic mucosa, and in monocytes isolated from colonic mucosa of ulcerative colitis patients. Circulating levels of IL-6 are high in patients with active Crohn's disease and consistently elevated in inflammatory bowel disease, where its sources are primarily macrophages and epithelial cells (27) Very little is known about cytokine profiles in esophagitis. We and others have recently reported that in human esophagitis, endoscopic mucosal biopsies contained elevated levels of IL-6, and patients with reflux esophagitis showed increased concentration of this proinflammatory cytokine in the inflamed tissue compared with controls (58) . IL-1␤ was detected in patients with more severe inflammation, whereas TNF-␣ was present sporadically and in low concentrations.
We have shown that induction of acute experimental esophagitis in the cat by repeated daily perfusion of 0.1 N HCl (45 min for 3 days) causes a dramatic decrease in amplitude of peristaltic contractions in the body of the esophagus in response to swallowing and in the amplitude of contractions in response to EFS (12) . In contrast, the response to direct myogenic stimulation by acetylcholine was not affected, suggesting that inflammation associated with esophagitis affects release of neurotransmitters responsible for esophageal contraction, without directly affecting the myogenic contractile machinery. This possibility was confirmed by direct measurement of ACh release in response to EFS. ACh release was reduced almost to basal levels, i.e., to the levels measured in the absence of EFS, confirming that in this model of experimental esophagitis, ACh release is almost abolished (12) . Incubation of in vitro circular muscle strips with the proinflammatory cytokine IL-1␤ or IL-6 reproduced the changes in contraction observed with esophagitis and, similar to esophagitis, inhibited release of ACh. The finding that IL-1␤ and IL-6 were elevated in the esophageal circular muscle from esophagitis animals supports the possibility that these cytokines may be part of the inflammatory mediators responsible for esophagitis-associated esophageal motor dysfunction (12) .
We therefore investigated whether IL-1␤ and IL-6 induce production of other inflammatory mediators to inhibit neurally mediated (but not myogenic) contraction of esophageal circular smooth muscle.
METHODS
Esophagitis model. Experimental procedures were approved by the Animal Welfare Committee of Rhode Island Hospital. Adult male cats weighing between 3.5 and 5.5 kg were used in this study. After an overnight fast, they were anesthetized with ketamine hydrochloride (10 mg/kg), and maintenance doses of ketamine (2.5-5 mg/kg) were administered as needed. To determine lower esophageal sphincter (LES) position, esophageal pressure was measured by a repeatedstation pull-through technique, 1-2 mm at a time, with a multilumen catheter having three proximal openings 3 cm apart. A distal perfused Dentsleeve was used to monitor sphincter pressure after the location of the high-pressure zone was established with the perfused side openings, and the three proximal openings measured the amplitude of contraction in the esophageal body. With the sleeve placed across the LES, the most proximal opening, which was 9 cm proximal to the LES, was used to perfuse 0.1 N HCl. The animals were kept on a slant board at a 15°angle during the perfusion to avoid aspiration. Before acid perfusion, the cat received 0.02 mg/kg atropine to prevent excessive secretion and 1.0 mg/kg im xylazine for anesthesia. After a 5-to 10-min period to allow the additional anesthetic to take effect, 0.1 N HCl was perfused into the esophagus at a rate of 1 ml/min for 30 to 45 min. After perfusion the cat was injected subcutaneously with 100 ml saline to prevent dehydration and received 0.01 mg/kg buprenorphine subcutaneously to maintain analgesia. After the animals were returned to their cages, they were monitored for signs of discomfort and were maintained on broth and a soft diet. The animals appeared alert and comfortable and ate normally.
In each experiment, two groups of animals were examined: the first group consisted of normal, untreated animals, whereas the second group (animals with esophagitis), after initial measurement of LES pressure, had their esophagus perfused with 0.1 N HCl over 3 consecutive days, and the esophagus was tested on the fourth day. This protocol has been shown to produce inflammatory changes in the esophageal mucosa and concurrent reduction in the LES in vivo resting pressure and in vitro spontaneous tone, whereas in sham-treated animals that had esophageal perfusion with distilled water, no effect on mucosa appearance or LES resting pressure was noted (6, 25) .
In a group of six animals, esophageal pressures were measured at 3 cm proximally to the LES during six successive swallows induced by introduction of 2 ml of water in the proximal esophagus. The pressure measurements were obtained on day 1, before beginning the acid perfusion, and on day 4, before euthanizing the animals.
Preparation of esophageal circular smooth muscle strips and tissue. Animals were initially anesthetized with ketamine (Aveco, Fort Dodge, LA), then euthanized with an overdose of phenobarbital (Schering, Kennilworth, NJ). The chest and abdomen were opened with a midline incision exposing the esophagus and stomach. The esophagus and LES were isolated and excised as previously described (7) . The esophagus and stomach were removed together and pinned on a wax block at their in vivo dimensions and orientation, as measured before dissection. The esophagus and stomach were opened along the lesser curvature. The high-pressure zone is characterized by a visible thickening of the circular muscle layer in correspondence of the squamocolumnar junction and immediately proximal to the sling fibers of the stomach. We have shown previously that a 5-to 8-mm band of tissue, coinciding with the thickened area, constitutes the LES and has distinct characteristics when examined in vivo in the organ bath. The mucosa and submucosal connective tissue were removed by sharp dissection, and the esophagus was excised beginning at 1 cm proximal to the thickened area and extending proximally to the smooth-striated muscle junction, which was visible to the naked eye. Two-millimeter esophageal circular muscle strips were mounted in separate 1 ml muscle chambers and equilibrated for 2 h with continuous perfusion of oxygenated physiological salt solution (PSS), as previously described in detail (14) .
To prepare esophageal muscle for PAF, PGE2, and H2O2 measurements, the circular muscle layer was cut into 0.5-mm thick slices with a Stadie Riggs tissue slicer (Thomas Scientific Apparatus, Philadelphia, PA), and tissue squares were made by cutting twice with a 2-mm blade block, the second cut at right angles to the first.
Measurements of muscle strip contraction. Full-thickness esophageal circular muscle strips 2 mm wide were cut with a blade block with blades held at a fixed (2 mm) distance. Strips were mounted in separate 1-ml muscle chambers as previously described in detail (14) . They were initially stretched to 2.5 g to bring them near conditions of optimum force development and equilibrated for 2 h while being perfused continuously with oxygenated PSS at 37°C. The PSS contained the following (in mM): 116.6 NaCl, 21.9 NaHCO3, 1.2 NaH2PO4, 3.4 KCl, 2.5 CaCl2, 5.4 glucose, and 1.2 MgCl. The solution was equilibrated with a gas mixture containing 95% O 2-5% CO 2 at 37°C, pH 7.4.
After equilibration, esophageal strips were stimulated with squarewave pulses of supramaximal voltage, 0.2 ms, 2-10 Hz, 8-s trains, delivered by a stimulator (Grass Instruments, model S48) through platinum wire electrodes placed longitudinally on either side of the strip. Muscle strips responded with a variable contraction ("on" contraction ) at the beginning of the stimulus and a more reliable and larger contraction after the end of the stimulus ("off" contraction ). All data reported are off contractions. We have reported previously (5) and more recently (12) that the off contraction is abolished by atropine, and thus it must be a contraction in response to release of ACh.
After the series of electrical stimulations ended, the strips were equilibrated for 30 min, then cumulative dose responses were obtained for ACh (10 Ϫ7 to 10 Ϫ4 M). It was previously shown (5) that bethanecol-induced contraction of cat esophageal circular muscle was not affected by large doses of TTX (3 ϫ 10 Ϫ5 ), supporting the view that ACh-induced contraction is myogenic.
To study the effect of IL-1␤ and IL-6 on contraction in response to EFS and ACh, after frequency-response and dose-response relationships in control conditions were obtained, the strips were incubated in the cytokines for 2 h, then contractions in response to EFS and ACh were obtained again. The concentration and incubation times for IL-1␤ (100 u/ml) and IL-6 (ng/ml) used in these experiments have been previously shown to mimic esophagitis-induced changes in esophageal smooth muscle contraction, i.e., they inhibited EFS-induced but not ACh-induced contraction. PAF and PGE 2 were dissolved in ethanol. When they were added to the muscle chamber, the highest concentration of ethanol in the chamber was 10 Ϫ5 M and had no effect on esophageal smooth muscle contraction.
ACh release. The release of ACh was measured using a wellestablished technique in which ACh stores in a circular smooth muscle preparation are previously labeled with [ 3 H]choline (18) . This technique has been used extensively to examine myenteric or submucosal plexus function of several species (62, 65) . Muscle strips were mounted in 1-ml muscle chambers as previously described (14) . Mounted strips were incubated for 1 h at 37°C in Krebs buffer containing 0.2 M [ 3 H]choline (80 Ci/mM; New England Nuclear, Boston, MA) and 50 M physostigmine. The strips were washed by changing the solution every 3 min for 1 h. After 1 h, the basal tritium release approached a plateau level. After incubation in [ 3 H]choline, the strips were washed three times with 1 ml Krebs containing 50 M physostigmine to inhibit ACh breakdown and 10 M hemicholinium to inhibit choline uptake. At this time, a 3-ml sample, resulting from washing the 1-ml chamber three times, was collected, pooled, and used to measure basal release. To measure EFS-induced ACh, release strips were stimulated with the appropriate frequency for 30 s. After 30 s, strips were washed three times with 1 ml of Krebs containing 50 M physostigmine and 10 M hemicholinium, and the 3-ml sample was collected for radioactivity measurement. Physostigmine and other cholinesterase inhibitors may have variable effects on ACh release, either enhancing (24, 66) or reducing it (4, 21, 22, 26, 37) depending on the type and function of the muscarinic receptors present in the tissue. Nevertheless, a cholinesterase inhibitor is necessary to prevent the enzymatic breakdown of ACh. Strips were allowed to rest 30 min before the next stimulation. Frequencies tested included 0.5, 1, 2, and 5 Hz. Under these experimental conditions, Collins et al. (18) reported that 90% of the radioactivity in the superfusate was [ 3 H]ACh, as measured by high-performance liquid chromatography (HPLC). The finding of a linear relationship between force developed and released counts per minute, as shown in Fig. 10 , indicates that counts per minute are a measure of ACh release in our preparation.
Measurement of H2O2 in smooth muscle tissue. Esophageal circular smooth muscle (100 mg) was homogenized in PBS buffer. Homogenization consists of a 20-s burst with a Tissue Tearer (Biospec, Racine, WI) followed by 50 strokes with a Dounce tissue grinder (Wheaton, Melville, NJ). An aliquot of homogenate (100 l) was taken for protein measurement. The homogenate was centrifuged at 15,000 rpm (2,500 g) for 15 min at 4°C in a Beckman J2-21 centrifuge with a fixed-angle JA-20 rotor (Beckman, Palo Alto, CA), and the supernatant was collected.
H2O2 content is measured by BIOXYTECH H2O2-560 quantitative hydrogen peroxide assay kit (OXIS International, Portland, OR). This assay is based on the oxidation of ferrous ions (Fe 2ϩ ) to ferric ions (Fe 3ϩ ) by hydrogen peroxide under acidic conditions. The ferric ion binds with the indicator dye xylenol orange {3,3Ј-bis[N,N-di(carboxymethyl)-aminomethyl]-o-cresoIsulfone-phthalein sodium salt} to form a stable colored complex that can be measured at 560 nm.
Measurement of PGE2 in smooth muscle tissue. Esophageal circular smooth muscle tissue (100 mg) was homogenized in PGE2 homogenization buffer [0.1 M phosphate buffer (pH 7.4) containing 1 mM EDTA, 20 ug/ml indomethacin] at 4°C. Homogenization consisted of 10-to 20-s bursts with a Tissue Tearer (Biospec) followed by 40 -60 strokes with a Dounce tissue grinder (Wheaton). The homogenate was centrifuged at 15,000 rpm at 4°C for 15 min. One hundred microliters of each sample supernatant were used for protein measurement. Two milliliters of supernatant were used for PGE 2 purification by affinity column (Cayman Chemical, Ann Arbor, MI). The resulting extracts were kept at Ϫ70°C. The PGE2 concentration was quantified by using a PGE 2 competitive enzyme immunoassay kit (Cayman Chemical).
Measurement of thromboxane B2 in smooth muscle tissue. Thromboxane A 2 is an unstable arachidonate metabolite with a half-life of 30 s. It rapidly decays nonenzymatically to the stable thromboxane B 2 (53) . We therefore measured thromboxane B2 as an index of formation of thromboxane A2. Normal esophageal circular muscle tissue was incubated in IL-6 (2 U/ml, 2.5 h), with or without 10
Ϫ7 M NS-398 [cyclooxygenase (COX)-2 inhibitor] or 10
Ϫ6 M SC-560 (COX-1 inhibitor). The solution was equilibrated with 95% O 2-5% CO 2 at 37°C, pH 7.4 for 2.5 h, then the supernatant and tissue were collected, immediately frozen in liquid nitrogen, and kept at Ϫ70°C until measurements were obtained. The measurements were normalized per protein content of the tissue. Protein content in each sample was measured by using the Bio-Rad protein assay kit (Bio-Rad Laboratories, Melville, NY). Thromboxane B2 was measured using the EIA Kit (catalog no. 519031) from Cayman Chemical.
Measurement of PAF in smooth muscle tissue. PAF was extracted from esophageal circular smooth muscle by a modification of the method of Bligh and Dyer (9) . One hundred micrograms of esophageal tissue squares were homogenized in 2 ml of methanol. One milliliter of homogenate was transferred to a tube containing 0.5 ml chloroform, 1 ml methanol, 0.4 ml H2O for a final ratio of 1:2:0.8 chloroform/methanol/H 2O (vol/vol/vol). The mixture was vortexed, left at room temperature for 1 h, then centrifuged (5,000 g for 5 min). The supernatant was transferred to another glass tube, and the pellet was reextracted with 3.8 ml of the chloroform/methanol/H 2O solution. The mixture was centrifuged again, and the two supernatants were combined. Two milliliters of chloroform and 2 ml 1 M NaCl were added, and the phases were separated by centrifugation (5,000 g for 5 min). The upper phase was aspirated and discarded, and the lower phase was washed once with 4 ml 1 M NaCl/methanol (9:1 vol/vol). Samples of this washed chloroform phase were dried under nitrogen and stored at Ϫ20°C. Measurement of PAF was performed within 72 h of extraction.
Measurement of tissue levels of PAF were made using the PAF-3 H-labeled scintillation proximity assay system (TRK 990; Amersham International, Amersham, UK). Scintillation proximity assay is a sensitive assay system that uses microscopic beads containing scintillant that emits light when radiolabeled molecules of interest bind to the surface of the bead.
Protein determination. The homogenates of esophageal tissues were solubilized by addition of 6 ml 0.1 N NaOH and heating the sample at 80°C for 30 min. The amount of protein present was determined by colorimetric analysis (Bio-Rad).
Materials and reagents. Human interleukin IL-1␤ and IL-6 were purchased from Pierce Endogen (Rockford, IL). The agents used were collagenase type II and soybean trypsin inhibitor from Worthington Biochemicals (Freehold, NJ), sodium dodecylsulfate from Bio-Rad, polyacrylamide from BDH Chemicals (Poole, England), and acetic acid from Malinkrokt Specialty Chemicals (Paris, KY). Acetylcholine, physostigmine, hemicholinium, saponin, BME amino acid supplement, creatine phosphate, creatine phosphokinase, ATP, antimycin A, and other reagents were purchased from Sigma (St. Louis, MO).
Statistical analysis. Data are expressed as means Ϯ SE. Statistical differences between means were determined by Student's t-test. Differences between multiple groups were tested using ANOVA for repeated measures and checked for significance using Scheffé's Ftest.
RESULTS

IL-1␤ and IL-6 cause production of PGE 2 and PAF through H 2 O 2 -dependent mechanisms.
We have previously reported (12) that experimental esophagitis significantly reduced EFSinduced (but not ACh-induced) contraction in cat esophageal circular smooth muscle strips (P Ͻ 0.001, ANOVA). Incubation of normal esophageal strips with IL-1␤ or IL-6 (but not TNF-␣) replicated these esophagitis-induced changes in esophageal motor function, as shown in Fig. 1 . The proinflammatory cytokines IL-1␤ and IL-6 (but not TNF-␣) are present in esophagitis at higher levels than in normal esophageal circular muscle and have been shown to affect production of inflammatory lipid mediators, such as PGE 2 and PAF (11, 33) , in several organ systems. We therefore investigated whether esophagitis or the associated increase in the levels of inflammatory cytokines IL-1␤ and IL-6 affect production of PGE 2 or PAF and whether these lipid mediators participate in esophagitis-induced motor dysfunction. Figure 2 shows that circular muscle content of PAF and of PGE 2 were significantly elevated in esophagitis specimens compared with normals (P Ͻ 0.05, ANOVA). Similarly, the levels of PAF and of PGE 2 increased significantly in normal esophageal circular muscle incubated in IL-1␤ (P Ͻ 0.05, ANOVA) and in normal esophageal circular muscle incubated in IL-6 (P Ͻ 0.05, ANOVA).
We have shown in LES that the esophagitis-induced decrease in resting tone was reduced by the H 2 O 2 scavenger catalase, suggesting involvement of H 2 O 2 (16) . We therefore tested the effect of catalase on PGE 2 and PAF production in response to IL-1␤ and IL-6. Figures 3 and 4 show that IL-1␤-and IL-6-induced production of PGE 2 and PAF were both significantly reduced by catalase (P Ͻ 0.05, ANOVA), suggesting involvement of H 2 O 2 . This possibility was investigated by examining production of PGE 2 and PAF in response to exogenously applied H 2 O 2 . Figure 5 shows that relatively short-term exposure (2 h) to both IL-1␤ and IL-6 significantly increased H 2 O 2 levels in normal esophageal circular muscle (P Ͻ 0.01, ANOVA). We have previously shown that IL-1␤ (100 U/ml) or IL-6 (1 ng/ml) reproduces the motor dysfunction found in esophagitis. At these concentrations, IL-1␤ and IL-6 increased H 2 O 2 to levels comparable with those induced by experimental esophagitis. Figure 6 shows that H 2 O 2 , in turn, causes a significant increase in the levels of PGE 2 and PAF in circular muscle of the esophagus (P Ͻ 0.01, ANOVA ).
The data presented so far suggest therefore that exposure of circular muscle to inflammatory cytokines, such as IL-1␤ and IL-6, causes production of H 2 O 2 in the circular muscle layer, which, in turn, causes an increase in the levels of PGE 2 and PAF, which may ultimately be responsible for reduction of contraction in response to EFS, without reducing the response to direct myogenic stimulation with ACh. If H 2 O 2 is central to this effect, exposure of the circular muscle to H 2 O 2 should produce the same effect as exposure to IL-1␤ or IL-6 or esophagitis. Figure 7 shows that 2-h incubation of circular muscle strips in H 2 O 2 (10 Ϫ4 M) caused a statistically significant decrease in contraction in response to EFS (P Ͻ 0.05, ANOVA) but did not significantly reduce contraction in response to direct stimulation with ACh.
PGE 2 Fig. 8A , PAF causes a reduction in the force developed. Both PGE 2 and PAF significantly reduced the contraction in response to EFS (P Ͻ 0.001, ANOVA) when used alone, and in combination they abolished EFS-induced contraction (Fig. 8A ) without affecting ACh-induced contraction (Fig. 8B) .
The data suggest that esophagitis and esophagitis-associated PGE 2 and PAF affect neural release of ACh, without affecting smooth muscle contractile mechanisms.
To confirm that ACh release in response to neural stimulation was damaged, we examined ACh release in response to EFS in normal and esophagitis specimens and in normal muscle strips incubated in IL-1␤ or IL-6 as well as PAF or PGE 2 . [ 3 H]ACh release, measured in the supernatant, increased with frequency of EFS, compared with levels in the absence of EFS (basal). We have previously shown that esophagitis, IL-1␤, or IL-6 significantly reduces ACh release (12) in response to EFS. Figure 9 shows that PAF and PGE 2 caused a Fig. 1 . Frequency-response curves for normal and esophagitis circular muscle strips. An acute model of experimental esophagitis was obtained by esophageal (ESO) perfusion with 0.1 N HCl for 45 min on 3 consecutive days, with experiments carried out on the 4th day. Amplitude of contraction in response to electrical (i.e., neural) stimulation was significantly reduced after acute esophagitis compared with normal specimens (P Ͻ 0.001, ANOVA). Incubation of normal ESO strips with IL-1␤ (100 U/ml, 1 h) or IL-6 (1 ng/ml, 1 h) also significantly reduced electrical field stimulation (EFS)-induced contraction (P Ͻ 0.001, ANOVA). ACh-induced contraction of ESO strips, however, was not affected after experimental esophagitis or by incubation of normal esophageal smooth muscle strips in IL-1␤ or IL-6, suggesting that esophageal circular muscle is not damaged by acid perfusion but that the release of excitatory neurotransmitters may be affected. Some of these data have been previously reported (12) . The experiments have been repeated in the present study and confirm the previous data. They are shown here for the readers' convenience. Values are means Ϯ SE for 3 cats. Fig. 2 . Esophageal circular muscle content of platelet-activating factor (PAF) and PGE2. PGE2 was purified using a PGE2 purification column and measured by enzyme immunoassay. PAF was extracted from esophageal circular smooth muscle by a modification of the method of Bligh and Dyer (9) and measured using the PAF-[ 3 H]scintillation proximity assay (SPA) system (Amersham International). PAF and PGE2 levels were significantly elevated in esophagitis specimens compared with normals (*P Ͻ 0.05, ANOVA). Similarly, the levels of PAF and of PGE2 increased significantly in normal esophageal circular muscle incubated for 2 h in IL-1␤ (100 U/ml) or IL-6 (1 ng/ml; *P Ͻ 0.05, ANOVA). Values are means Ϯ SE for 6 normal and esophagitis cats and 3 for normal ESO treated with IL-1␤ or IL-6. significant reduction in ACh release (P Ͻ 0.001, ANOVA) that was comparable with the reduction induced by IL-1␤ or IL-6 and only slightly less pronounced than the reduction caused by esophagitis.
To demonstrate that the released radioactivity was due to ACh release, we compared forces and counts per minute obtained at the same parameter of EFS, as shown in Fig. 10 . We have previously shown that EFS-induced esophageal contraction is nearly abolished by atropine and thus almost entirely dependent on neural release of ACh (5, 12) . The finding of a linear relationship (r ϭ 0.98) between contraction and released counts per minute indicates that the counts per minute measured represent ACh release.
To show that the reduction in contraction is due to cytokineinduced formation of PAF and PGE 2 , we examined EFSinduced contraction in the presence of the PAF receptor antagonist CV3988 and in the presence of the prostaglandin synthesis inhibitor indomethacin (Fig. 11) .
As shown in Fig. 1 , IL-1␤ or IL-6 almost abolished EFSinduced contraction. The reduction by IL-1␤, however, was partially blocked by CV3988 (P Ͻ 0.001, ANOVA) or by indomethacin (P Ͻ 0.001, ANOVA) when used alone and was completely reversed when CV3988 and indomethacin were used in combination (Fig. 11) . This finding suggests that production of PAF and PGE 2 , formed in response to IL-1␤, may fully account for the substantial reduction in ACh release and contraction occurring in our model of experimental esophagitis. Figure 12 shows that the IL-6-induced reduction in contraction in response to EFS was partially reversed by the PAF antagonist CV3988 (P Ͻ 0.001, ANOVA) but was not affected by the COX inhibitor indomethacin. This was surprising because, as shown in Figs. 2 and 3 , IL-6 increases PGE 2 and PGE 2 clearly inhibits EFS-induced ACh-dependent contraction. We therefore examined whether IL-6 may induce formation of other arachidonic acid (AA) metabolites that would counterbalance the effect of PGE 2 . If that were the case, indomethacin, by inhibiting both, would have no effect. We therefore measured thromboxane formation in response to IL-6. Because thromboxane A 2 is an unstable arachidonate metabolite that rapidly decays to the stable thromboxane B 2 (53), we measured thromboxane B 2 as an index of formation of thromboxane A 2 . Figure 13A shows that IL-6 caused formation of thromboxane A 2 /B 2 as well as PGE 2 . Thromboxane A 2 /B 2 formation was inhibited by the COX-1 inhibitor SC-560, whereas PGE 2 Fig. 4 . Normal esophageal circular muscle was incubated for 2.5 h in IL-1␤ (100 U/ml) or IL-6 (1 ng/ml) in the presence or absence of catalase (780 U/ml). Catalase significantly reduced IL-1␤-and IL-6-induced production of PAF (*P Ͻ 0.05, ANOVA). Values are means Ϯ SE for 3 cats. formation was blocked by the COX-2 inhibitor NS-398. Figure  13B shows that IL-6 inhibited the contraction in response to EFS and that the inhibition was partly reversed by the TXA 2 receptor agonist U46619 and by the COX-2 inhibitor NS398.
Taken together, Fig. 13, A and B, confirm that IL-6 causes formation of PGE 2 , which reduces contraction in response to EFS and of thromboxane A 2 /B 2 , which increase it.
DISCUSSION
ACh is proven to be a neurotransmitter in cat esophageal circular muscle, as atropine nearly abolishes contraction of in vitro circular muscle strips in response to EFS (5, 12) . Induction of experimental esophagitis by perfusion with HCl reduced EFS-but not ACh-induced contraction of esophageal circular muscle (12) , suggesting that esophagitis impairs neurotransmitter release. IL-1␤ and IL-6 are produced in esophagitis and reproduce these changes in normal esophageal muscle (12) . These inflammation-induced changes are similar to those reported by Collins and colleagues (18, 19, 28) in Trichinella spiralis-infected rodents. Trichinella spiralis infection induced an acute inflammatory response in intestinal muscle of rats and mice resulting in suppression of neurotransmitter release, such as ACh and norepinephrine, by enteric (18) . [ 3 H]ACh release from normal strips, measured in the supernatant, increased with frequency of EFS, compared with levels in the absence of EFS (Basal). EFS-induced release of ACh was significantly reduced (P Ͻ 0.01, ANOVA) in muscle strips from esophagitis animals and from normal muscle strips incubated for 2 h in PGE2 (10 Ϫ5 M), PAF (10 Ϫ5 M), IL-1␤ (100 U/ml), and IL-6 (1 ng/ml). All experiments were performed in the presence of physostigmine (50 M) to prevent ACh breakdown. Some of these data have been previously reported (12) . The experiments have been repeated in the present study and confirm the previous data. They are shown here for the readers' convenience. Values are means Ϯ SE for 3 cats.
nerves. The proinflammatory cytokines IL-1␤ and TNF-␣ released from macrophages were reported as potential mediators of the functional alterations because 1) administration of exogenous IL-1␤ and TNF-␣ to normal control tissue mimicked the impairment of neurotransmitter release from longitudinal muscle-myenteric plexus observed during Trichinella spiralis infection; 2) increased mRNA expression of these cytokines was present in the longitudinal muscle-myenteric plexus of infected animals; and 3) macrophage depletion prevented the suppression in [ 3 H]ACh release (28, 35, 44) . Trichinella-induced inflammation, however, increased the amplitude of intestinal smooth muscle contraction (8, 51, 70, 71) , whereas HCl-induced inflammation of the esophagus did not affect the circular muscle response to ACh but reduced release of ACh from intramural neurons, decreasing the amplitude of neurally mediated contraction.
Unlike this well-explored model of Trichinella-induced inflammation and in agreement with human esophagitis (58), our esophagitis cat model does not involve TNF-␣, but only IL-1␤ and IL-6. We therefore examined the role of IL-1␤ and IL-6 in this motor dysfunction.
Inflammation and inflammatory mediators such as IL-1 (3) cause activation of inflammatory phospholipase A2 (PLA2) and production of reactive oxygen species (ROS). ROS and PLA2 may both cleave phosphatidylcholine into AA and lyso-PAF, a PAF precursor (46) . The AA liberated is converted to PGE 2 , possibly by COX-2, which is induced by inflammatory stimuli. The remaining lysophosphatidylcholine may be reincorporated into the cell phospholipid pool or, by enzymatic or nonenzymatic processes, may be cleaved further to produce PAF or PAF-like lipids.
We show that these products of PLA 2 -dependent phosphatidylcholine metabolism, i.e., PGE 2 and PAF (or PAF-like lipids) are the major mediators in esophageal injury associated with esophagitis. These lipids may be formed enzymatically or their analogs may be produced nonenzymatically through lipid peroxidation.
Enzymatic and nonenzymatic production of PGE 2 . IL-1␤ induces expression of sPLA2, COX-2, and PGE 2 synthesis (34, 41, 43) , sometimes resulting in synthesis of IL-6 (2, 32, 40, 42, 54, 55, 69, 73) .
In addition IL-1␤ and IL-6 may induce production of ROS (47, 67, 72a) . ROS have high affinity for lipids, causing lipid peroxidation. Free radical-induced peroxidation of AA (49) results in formation of isoprostanes, which are stable prostaglandin-like compounds that are formed enzymatically and nonenzymatically in vivo.
Many of the effects of 8-isoprostanes are mediated through prostanoid receptors; for instance, 8-iso-PGE 2 has been re- Fig. 8A (Normal, PGE2, and PAF) were plotted against the counts/minute (cpm) increase above basal, shown in Fig. 9 . Each data point represents the force and cpm obtained for a given stimulus. For instance, stimulating an untreated (Normal) esophageal strip at 0.5 Hz produced 1.6 g of force and 202 cpm of released radioactivity, as shown here. The figure demonstrates a linear relationship between cpm (i.e., ACh release) and force developed. Fig. 11 . Frequency-response curves for normal circular muscle strips incubated for 2 h in IL-1␤ (100 U/ml) alone (OE) or in combination with indomethacin (10 Ϫ5 M; ‚), indomethacin and CV3988 (10 Ϫ5 M; F), and indomethacin and CV3988 (E). IL-1␤ significantly reduced esophageal contraction in response to EFS (P Ͻ 0.001, ANOVA). This reduction was significantly reduced by indomethacin (P Ͻ 0.001, ANOVA) and by CV3988 (P Ͻ 0.001, ANOVA). Contraction was completely restored with indomethacin and CV3988 in combination. Values are means Ϯ SE for 3 cats. ported to inhibit ACh release in guinea pig tracheal muscle by acting at prostaglandin E 3 (EP 3 ) receptor subtypes (17) .
Enzymatic and nonenzymatic production of PAF. After PLA2 cleaves phosphatidylcholine into AA and lyso-PAF, PAF biosynthesis may occur via a "remodeling pathway," in which 1-0-alkyl-2-lysoglycero-3-phosphocholine/acetyl CoA acetyltransferase catalyzes the acetylation of inactive lyso-PAF into bioactive PAF (57) . This pathway is activated when a variety of cells (1) are challenged with IL-1␤.
The finding that the H 2 O 2 scavenger catalase significantly reduces PGE 2 and PAF formation in response to IL-1␤ supports a role of H 2 O 2 in the production of these lipid mediators. In this pathway, IL-1␤ binds to IL-1␤ receptors, a subfamily of IL-1␤-Tll-like receptors (45) , resulting in activation of NADPH oxidase, a cytosolic enzyme similar to neutrophil NADPH oxidase that produces H 2 O 2 independently of NADH and of the mitochondrial respiratory process (39, 48, 68) .
Unlike IL-1␤, IL-6 signaling is mediated by a cell surface signaling assembly composed of IL-6, the IL-6␣ receptor, and the shared signaling receptor gp130. IL-6 is first engaged by IL-6R␣ and then presented to gp130 in the proper geometry to facilitate a cooperative transition into a high-affinity signaling complex (31) . gp130 Is a shared cell-surface signaling receptor for at least 10 different hematopoietic cytokines (10) . IL-6-type cytokines, via the signal transducer gp130, activate the JAK/ STAT and MAPK cascades resulting in gene expression.
Cytokine-induced production of PGE 2 and PAF may depend on formation of H 2 O 2 as an inflammatory intermediate (39) , may be H 2 O 2 independent and associated with enzymatic action of PLA 2 , or may be any combination of the two. The finding that H 2 O 2 does not cause complete abolition of contraction in response to EFS, as shown in Fig. 7 , and that the H 2 O 2 scavenger catalase does not completely abolish PAF and PGE 2 production in response to IL-1␤ and IL-6, as shown in Figs. 3 and 4 , suggests that H 2 O 2 may be partly responsible for the formation of PAF and PGE 2 .
The synthesis of PAF is carefully controlled, but the formation of potent PAF mimetics after oxidation of phosphatidylcholines (60, 63) is unregulated. Because the structure of these bioactive lipid products differs from PAF whose sn-2 residue is exclusively derived from acetyl CoA, these phospholipids are termed "PAF-like." Precise quantitation of PAF-like lipids is difficult because oxidation of phosphatidylcholines generates a large number of modified phospholipid products, some of which do not stimulate the PAF receptor whereas others activate PAF receptor in a variety of experimental preparations (30, 60, 63) , and their biological activity is completely blocked by specific PAF receptor antagonists (30) . Because of their heterogeneity, we cannot separate the effects of enzymatically produced PAF from those caused by oxidatively produced PAF-like lipids.
PGE 2 and PAF (and H 2 O 2 ) inhibit ACh release. PAFinduced neurotoxicity has been demonstrated in human and rat culture systems (29) . Consistent with our findings, PAF has been shown to inhibit neurotransmitter release from rat brain slices and was selective for K ϩ depolarization-induced ACh release but did not affect release of other neurotransmitters (72) .
In addition, PAF increased the release of PGE 2 from astrocyte-enriched cortical cell cultures, and this effect was mimicked by the nonhydrolyzable PAF analog methylcarbamyl-PAF, by the PAF intermediate lyso-PAF, and by AA, supporting the view that intracellular PAF may be a physiological stimulus of PGE 2 production (64). PGE 2 (23, 36, 52, 56, 59, 74) and the structurally related E-ring 8-isoprostanes, resulting from lipid peroxidation, have been shown to inhibit release of ACh from cholinergic neurons in airway smooth muscle preparations, whereas the opposite effect has been reported in guinea pig ileal preparations (15, 38, 50) . The difference in the effects of PGE 2 may be related to different prostaglandin E receptor subtypes present in the different preparations. For instance, PGE 2 contracts gall bladder smooth muscle by acting on EP 4 receptors but relaxes LES smooth muscle. In this respect, esophageal smooth muscle is different from ileal muscles and similar to airway muscle. In guinea pig trachea, the isoprostanes 8-iso-PGE 1 and 8-iso-PGE 2 and the selective EP 3 -receptor agonist sulprostone suppressed EFS-evoked ACh release, and the inhibition was re- Fig. 13 . A: concentration of PGE2 and thromboxane (TX)B2 in supernatant of muscle strips incubated for 2.5 h with IL-6 alone, together with the cyclooxygenase (COX)-2 inhibitor NS398, or the COX-1 inhibitor SC560. IL-6 increased production of TXA2/B2 and PGE2, compared with untreated strips (control). PGE2 production was reduced by the COX-2 inhibitor NS-398, TX production was reduced by the COX-1 inhibitor SC-560. B: contraction in response to EFS (0.2 ms, 2 Hz, supramaximal voltage) in strips incubated in IL-6 alone or together with the TXA analog U46619 or the COX-1 inhibitor SC-560 or with the COX-2 inhibitor NS-398. As expected, IL-6 reduced the amplitude of contraction, the TXA analog U46619 and the COX-2 inhibitor partly reversed the IL-6-induced reduction, and the COX-1 inhibitor had no effect compared with 1L-6 alone. Values are means Ϯ SE for 3 experiments. *Statistically significant (P Ͻ 0.05, ANOVA) differences with respect to untreated strip. **Statistically significant (P Ͻ 0.05, ANOVA) differences with respect to strips incubated in IL-6 alone.
duced by a highly selective EP 3 -receptor antagonist (17) . Consistently with previously reported data (61), these findings suggest that PGE 2 and the E-ring 8-isoprostanes inhibit EFSevoked ACh release from cholinergic nerves innervating guinea pig trachea by interacting with prejunctional prostanoid receptors of the EP 3 subtype.
Our data demonstrate that PAF and PGE 2 affect ACh release, without interfering with ACh-activated contractile mechanisms and reproduce the effects of acid-induced esophagitis on esophageal contraction. PAF and PGE 2 in combination almost abolish EFS-induced contraction. The finding that the response to ACh is not affected by esophagitis (or PAF, PGE 2 , IL-1␤, or IL-6) excludes the possibility that inhibitory products that act directly on muscle (such as, for instance, NO) may contribute to the reduced contraction observed in esophagitis muscle strips. Conversely, the prostaglandin synthesis inhibitor indomethacin and the PAF antagonist CV3988, when used in combination, abolish IL-1␤-induced inhibition of contraction in response to EFS. These findings support the possibility that IL-1␤-induced formation of PAF and PGE 2 are the mediators of esophagitis-associated dysmotility.
Similar to IL-1␤, IL-6-induced inhibition of contraction in response to EFS, was reduced by the PAF antagonist CV3988. IL-6-induced inhibition, however, was not affected by indomethacin, although IL-6 caused production of PGE 2 , as shown in Figs. 2 and 3 . We first thought that inclusion of nonenzymatically produced 8-Iso-PGE 2 in our measurements of PGE 2 might provide an explanation for these findings, because 8-Iso-PGE2 may be indistinguishable from PGE 2 under assay conditions. If 8-Iso-PGE 2 were formed through H 2 O 2 -dependent lipid peroxidation, indomethacin would have little or no effect in reducing IL-6-induced inhibition of contraction. If that were the case, however, and IL-6 produced more PGE 2 via a noncyclooxygenase mechanism, through formation of H 2 O 2 , catalase would have a greater effect on the IL-6 response compared with IL-1␤. The respone to catalase, however, was the same in IL-6-and in IL-1␤-treated strips. This consideration forced us to look for a different explanation. We therefore examined whether IL-6 may induce the formation of other AA metabolites that would counterbalance the effect of PGE 2 . If that were the case, indomethacin, by inhibiting both, would have no effect. We therefore measured thromboxane formation in response to IL-6. IL-6 caused not only production of PGE 2 , as expected, but also induced formation of thromboxanes, which enhanced contraction in response to EFS, possibly by facilitating EFS-induced ACh release. It is notable that the thromboxane receptor agonist U46619 did not directly cause contraction of esophageal strips, when used alone (data not shown), but partly reversed IL-6-induced inhibition of contraction in response to EFS, suggesting that thromboxane affects mainly neural stimulation, possibly by increasing release of ACh. IL-6-induced formation of thromboxanes was COX-1 dependent, whereas formation of PGE 2 was COX-2 dependent, as has been previously demonstrated in other models of inflammation (41, 43) . This explains why indomethacin, by inhibiting both, had no net effect on IL-6-induced inhibition of muscle strip contraction, as shown in Fig. 12 .
In summary, IL-1␤ increased production of PGE 2 and PAF, both of which may occur enzymatically or through H 2 O 2 -mediated mechanisms. PGE 2 (or 8-Iso-PGE 2 ) and PAF (or PAF-like) cause inhibition of ACh release, without affecting muscle contraction in response to direct administration of ACh. IL-6 causes production of PAF, PGE 2 , and thromboxanes. The thromboxanes balance out PGE 2 -induced inhibition, so that PGE 2 and thromboxanes have no net effect. PAF, by itself, as shown in Fig. 12 , does not account for the entire inhibition in response to IL-6. The IL-6-induced inhibitor that, together with PAF, causes complete inhibition of EFS-induced contraction is presently unknown.
It should be noted that inflammation affects different contractile mechanisms in esophageal and LES circular muscle layers. PGE 2 and PAF affect ACh release from neurons without affecting esophageal muscle contraction in response to ACh. Thus, in the body of the esophagus, these inflammatory mediators have an effect on neurons and no effect on muscle. This is different from LES muscle, where PAF and PGE 2 reduce myogenic tone.
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